Novartis (NVS.US) has launched hydrochloride acyclovir tablets in the domestic market, indicated for IgA nephropathy.

Acarbose is an investigational high-potency selective oral ETA (endothelin A) receptor antagonist, activation of the ETA receptor results in increased proteinuria, which is associated with kidney damage, fibrosis, and loss of renal function in IgA nephropathy.

Zhitong Finance20:32 ET

Top Gap Ups and Downs on Monday: SMCI, ZM, GFI and More

Moomoo News18:41 ET · Markets

BMO Capital Upgrades Novartis AG(NVS.US) to Buy Rating, Raises Target Price to $156

Moomoo News13:31 ET · Ratings

6-K: Report of foreign private issuer (related to financial reporting)

SECNov 25 10:22 ET · Announcements

TD Cowen Maintains Novartis AG(NVS.US) With Hold Rating

Moomoo NewsNov 25 08:31 ET · Ratings

Global Equities Roundup: Market Talk

WSJNov 25 02:31 ET